Aethoxysklerol 3%

0.25% solution for injection for intravenous use: lauromacrogol 400: 5 mg. Solution for injection for intravenous use: lauromacrogol 400 10 mg. 1% solution for injection for intravenous use: lauromacrogol 400 20 mg. 2% solution for injection for intravenous use: lauromacrogol 400 40 mg. 3% solution for injection for intravenous use: lauromacrogol 400 60 mg.

0.25% and 0.5% solutions: sclerosing therapy of small varices (reticular varices) and teleangectasia. 1% solution: sclerosing therapy of small varices (reticular varices) and the central branch of teleangectasis. 2% solution: sclerosing therapy of medium-sized varicose veins. 3% solution: sclerosing therapy of large-caliber varicose veins and hemorrhoids (first and second degree).

In general, the dose of lauromacrogol 400 should not exceed 2 mg per kg of the patient's body weight (for a patient of 70 kg it therefore means a dosage of 56 ml of the 0.25% solution, 28 ml of the 0.5% solution, 14 ml of the 1% solution, 7 ml of the 2% solution, 4.6 ml of the 3%%). During the first treatment to patients prone to allergic reactions inject only one injection.If no allergic form occurs and depending on the size of the area to be sclerosed, multiple injections can be injected, without exceeding the maximum recommended dosage. Small varicose veins: depending on the size of the varicose veins inject inside the vessel 0.1-0.3 ml 0.25% or 0.5% solution%. Teleangectasis: depending on the area to be clerotized intravasally inject 0.1-0.2 ml of 0.25% - 0.5% solution - 1%. Varicose veins of medium and large caliber: intravasally inject 0.5-1 ml of 2% Solution-3%. Sclerosing therapy of hemorrhoids: during each treatment session, a total of 3ml of solution should not be s ufied.%. In accordance with the diagnosis, a maximum of 1 ml should be administered, strictly as a submucosal injection for each hemorrhoid. When treating a hemorrhoid at 11 o'clock in a man, the amount injected should not exceed 0.5 ml. Sclerosing therapy of varicose veins of the lower extremities: perform the injection to horizontal patient with limb raised by about 30-45 degrees after disinfection of the affected area, inject inside the vein, using very thin needles and 2 ml syringes, keeping them almost parallel to the skin. Compress the inoculation area for about 1 minute. After applying a protective patch to the injection site, the limb should be subjected to sufficient elastic compression, after which the patient should walk for 30 minutes, possibly in the vicinity of the doctor's office. The bandage should be worn for 2-3 days (small vessels) and for 4-6 weeks (medium and large vessels). In cases of large sclerotized areas, an elasto-compressive bandage is recommended. Good results were obtained by increasing compression at the injection site using a dental wadding roll. The effectiveness of sclerotherapy depends very much on the subsequent compression treatment. For this reason, the limb must always be raised and must be restored to the mo ment of standing up even if for a short time. Sclerosing therapy of hemorrhoids: the injection should be strictly submucosal, directly into the hemorrhoid or its adjacencies (cranial to it) within the tissue surrounding the blood vessels. Particular attention should be paid to the region of the anal sphincter muscle, for the risk of damage and consequent incontinence problems. When treating a hemorrhoid at 11 o'clock in a man, the amount injected should not exceed 0.5 ml of 3% solution due to the proximity of the urethra and prostate. Depending on the degree of hemorrhoidal pathology, several treatments may be required at intervals of 1-2 weeks

Hypersensitivity to the active substance or to any of the other ingredients. Patients with severe acute systemic diseases (especially untreated). Sclerosing therapy of varicose veins of the lower extremities is absolutely contraindicated in: non-walking patients, patients suffering from arterial occlusive diseases (Fontaine stage III and IV), patients suffering from thromboembolic diseases. Patients at high risk of thrombosis (E. G.. patients with hereditary thrombophilia or patients with multiple risk factors such as taking hormonal contraceptives or hormone replacement therapy, obesity, smoking and long periods of immobility). During the first trimester and after the 36th week of gestation specific contraindication of sclerosing therapy of hemorrhoidal pathologies is, in addition, acute inflammation of the anal region

> > Sclerosing therapy of varicose veins: local adverse reactions (e.g.. necrosis), in particular of the skin and subcutaneous tissues (and, in rare cases, nerves) in the treatment of varicose veins of the lower extremities following accidental injection into the surrounding tissues (paravenous injection). The risk increases with increasing concentrations and volume of the drug. In addition, it was observed the following adverse reactions and the frequency of occurrence is specified below: very common (>1/10), common (>= 1/100 - = 1/1000 - = 1/10000 - >Therapy sclerosing diseases hemorrhoidal: in the treatment of pathologies hemorrhoidal reactions were observed adverse local as burning, pain, disorders and feeling pressure both during and after the injection, especially in patients disesso male with hemorrhoids located at 11 (the area of the prostate). Such reactions are temporary and, in rare cases, can last for 2-3 days. In addition, the following adverse reactions have been observed whose frequency of occurrence is specified below: very common (>=1/10), common (>= 1/100 - = 1/1000 - = 1/10000 -